InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Patent Office chief takes government contacts to Howrey


Todd Dickinson hopes to develop a strong regulatory focus in his new role as co-chair of Howrey Simon Arnold & White’s IP prosecution and licensing group

Todd Dickinson, former USPTO director, is keen to capitalize on some of his government contacts after becoming Howrey Simon Arnold & White's co-chair of IP last week.

As joint head of IP licensing, counseling, prosecution and patent portfolio management, the ex-Patent Office chief has set his sights on building ties with Congress and the US administration with a view to strengthening the firm's regulatory focus....


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

The week in IP - @mdloney's round-up: Ford, Google, Oracle, patent grants, Led Zep, trolls http://t.co/AjdMvgYP3B http://t.co/vKhF6mUyAV

May 29 2015 07:28 ·  reply ·  retweet ·  favourite
ManagingIP profile

@TGraulund @jakobballing That does seem the most likely reason. But it may backfire if companies cut back on filings!

May 29 2015 04:18 ·  reply ·  retweet ·  favourite
ManagingIP profile

@TGraulund If anyone could explain the logic behind putting fees up by this amount, in current business environment, we'd be grateful!

May 29 2015 02:58 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


INTA Daily News 2015

Read this year's INTA Daily News - published daily by Managing IP direct from the INTA Annual Meeting in San Diego


June 2015

The fine line between abuse and fair use at the PTAB

Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system



Most read articles

Supplements